Clinical Trials5 October 2026
What the New UK Clinical Trials Regulations Mean for Sponsors
The UK's new clinical trials regulations enter force 28 April 2026. Here is what the notification scheme, combined review, and results disclosure obligations mean for sponsors and CROs.
Treatments28 September 2026
Biocon Pertuzumab Biosimilar Pebrilzo Wins CHMP Opinion
Biocon's pertuzumab biosimilar Pebrilzo has received a positive CHMP opinion — the first monoclonal antibody biosimilar under the EMA's tailored clinical development approach for HER2-positive breast cancer.
Treatments24 September 2026
FDA Approves Imlunestrant Combination for ESR1 Breast Cancer
The FDA has fully approved imlunestrant plus abemaciclib for ESR1-mutated ER-positive breast cancer, with EMBER-3 showing 11.1 vs 5.5 months PFS. Read on.